Home/Pipeline/Not Specified (Oncology Focus)

Not Specified (Oncology Focus)

Cancer

Pre-clinicalActive

Key Facts

Indication

Cancer

Phase

Pre-clinical

Status

Active

Company

Narwhal Bio

About Narwhal Bio

Narwhal Bio is an early-stage biotech leveraging advanced cell engineering to develop therapies for oncology and immunology. The company is building a platform to create more precise and effective engineered immune cells, targeting significant unmet needs in cancer and autoimmune conditions. As a private, pre-clinical entity, it is positioned in the competitive but high-potential cell therapy space. Its success will depend on translating its platform technology into clinically validated treatments.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases

Other Cancer Drugs

Drug	Company	Phase	Status
EDM Platform for Genetic Medicine	Coastar Therapeutics	Pre-clinical	Platform Development
CO-1	Caedo Oncology	Pre-clinical	Active R&D
Anti-CD99 monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Anti-HLA class I monoclonal antibody	Caedo Oncology	Discovery/Pre-clinical	Proprietary antibody identified
Triapine®	Nanopharmaceutics	Clinical	Active
Ammonium Tetrathiomolybdate	Nanopharmaceutics	Clinical	Active
Aza-TdC	Nanopharmaceutics	Clinical	Active
Undisclosed Oncology Program(s)	Cell BioEngines	Phase 1	Active
No-alpha IL-2 Mutein	SarcoMed USA	Pre-clinical	Active
PMIS Therapeutic	NaturemiRI	Preclinical/Clinical (unspecified)	Active
AUM302 (formerly IBL-302)	Inflection Biosciences	Pre-clinical (partnered)	Active
Undisclosed DDR Sensor Program(s)	NERx Biosciences	Pre-clinical	Active